Senseonics Holdings went into this report as a high growth, high expectation diabetes tech stock, and the market clearly liked what it saw. The share price jumped about 36% to US$7.02 the day after earnings, a big move for a medical device company still posting sizeable losses.

The headline is simple: strong revenue traction in continuous glucose monitoring and a sharp lift in gross margin grabbed investors’ attention, even though Senseonics reported a net loss of US$36.7 million for the quarter. The stock is now trading as if this revenue and margin story can keep building.

Is Senseonics Holdings suddenly priced for perfection after this 36% jump, or do the losses and rich P/S multiple still dominate the story? See how revenue growth, margins and dilution factor into our valuation analysis for Senseonics Holdings

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$14.483 million vs. US$6.649 million (revenue increased strongly year on year)
• Net Loss (Q2 2026 vs. Q2 2025): Net loss of US$36.705 million vs. net loss of US$14.501 million (loss widened year on year)
• Basic EPS (Q2 2026 vs. Q2 2025): Loss of US$0.63 per share vs. loss of US$0.36 per share (per share loss increased year on year)
• Trailing 12-Month Revenue and Net Loss (Q2 2026 TTM vs. Q2 2025 TTM): Revenue of US$48.545 million and net loss of US$109.391 million vs. revenue of US$25.466 million and net loss of US$68.212 million (higher revenue alongside a larger cumulative loss)

Prefer clean charts instead of staring at rows of numbers and footnotes? Get a full visual picture of Senseonics Holdings, including how the market is valuing the stock after this earnings reaction, in our company report for Senseonics Holdings.

Senseonics Bull Case Meets Real Adoption Milestones

Bulls argue Senseonics can turn Eversense 365 into a sticky, recurring revenue platform built on faster adoption, better access and solid reimbursement. Q2 gives some real proof points. Revenue reached US$14.5 million with U.S. sales of US$12.6 million and management lifted both full year revenue and gross margin guidance. That aligns with the idea that patient starts and reorders are supporting a larger, higher quality revenue base.

The thesis also hinges on distribution and access. Active prescribers rose about 130% year on year, Eon Care handled about 40% of U.S. insertions in Q2 and is targeting more than half by year end. Around 60% of U.S. revenue now runs through bundled reimbursement, backing the claim that payer structures are becoming more supportive. Integration with the twiist pump and strong real world usage data further support the view that Eversense can hold patients once they start.

Compare Senseonics Holdings’ revenue guidance, margin targets, and adoption metrics with where the stock is already trading after a 36% move. See the consensus price target analysis for Senseonics Holdings

Senseonics Bear Fears On Losses Largely Intact

The central bearish worry on Senseonics Holdings is that revenue traction will not offset heavy cash burn and that profitability will stay distant. This quarter does little to ease that concern. Revenue reached US$14.5 million and gross margin hit about 59%, yet the net loss widened to US$36.7 million with a loss of US$0.63 per share. Bears have argued that bringing commercialization in house would inflate SG&A and R&D, and Q2 supports that. SG&A rose sharply to US$32.9 million and R&D to US$11.6 million as Gemini and Freedom move forward.

Another bearish claim is that growth depends on sustained reimbursement and retention while operating costs stay elevated. Management still guides to 2026 operating expenses of US$150 million to US$160 million and cash use of US$110 million to US$120 million. That reinforces the view that Senseonics will likely need continued, disciplined execution over time before the loss profile improves.

After heavy cash use, widening losses and ongoing shareholder dilution, are these pressures just starting? Review our full risk analysis for Senseonics Holdings which shows 3 important warning signs

Take Control of Your Next Move

If the sharp 36% post earnings move in Senseonics Holdings has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the revenue and loss profile develops. Once you decide to build a position, use the Portfolio Command Center to cut through noise and stay focused on the most important updates that affect your holdings. Over the longer term, tap into crowd insights and differing views through the Community to stress test your own thinking. By spotting potential catalysts and risks early, you can make faster, more confident decisions and stay ahead of the market.

Seeking Alternatives Beyond Senseonics Holdings

Fresh stock ideas can move from quiet to flying once the crowd catches on. Scan these under the radar lists before momentum runs away and entry points start dropping. Act now.

• Spot sturdier compounders that can keep portfolios grounded while others chase the latest story by reviewing the curated list: list of solid balance sheet and fundamentals stocks (49 results).
• Ride the next wave of automation momentum before headlines catch up by checking the curated list: 36 robotics and automation stocks.
• Target companies already building the backbone of AI capacity while it still flies under most radars by assessing the hand picked list: 55 AI infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.